Hologic closes $4B Gen-Probe buyout | Wall Street Beat

August 2, 2012 by MassDevice staff

Hologic completes its $4 billion acquisition of Gen-Probe and puts up solid numbers for its fiscal 3rd quarter, sending shares up nearly 3% since July 30.

MassDevice.com Wall Street Beat

Hologic (NSDQ:HOLX) said its nearly $4 billion buyout of molecular diagnostics giant Gen-Probe (NSDQ:GPRO) is in the books, a day after Gen-Probe's shareholders OK'd the $82.75-per-share deal.

The acquisition, valued at about $3.7 billion, puts Hologic in the top tier of the diagnostics space, outside of its traditional market, women's health.

Hologic said the deal should add 20¢ per adjusted share during fiscal 2013 and should be "significantly more accretive" thereafter.

Sign up to get our free newsletters delivered straight to your inbox

News of the deal's closure, and strong fiscal 3rd-quarter numbers, has helped add 2.7% to HOLX shares since July 30. The stock closed at $18.75 yesterday, up from an $18.26 close July 30.

Hologic reported profits of $23.6 million, or 9¢ per share, on sales of $470.2 million during the 3 months ended June 23, for top-line growth of 4.2% but a bottom-line slide of 34.8%.

Adjusted for 1-time items, however, including $5.1 million in acquisition costs and a $1.7 million charge for the wind-down of its Adiana female sterilization line, EPS hit 35¢, just a penny shy of analysts' expectations.

Hologic moved to ditch its Adiana permanent female sterilization system after it lost a patent infringement lawsuit to Conceptus (NSDQ:CPTS).

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp